| Document |
Document Title |
|
WO/2021/254005A1 |
An immunosuppressant having the structure of formula (I), and a preparation method therefor and the use thereof. The series of compounds of the present invention can be widely used in the preparation of drugs for preventing and/or treati...
|
|
WO/2021/250541A1 |
Described herein are compounds of Formula I and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compoun...
|
|
WO/2021/252781A1 |
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or d...
|
|
WO/2021/249319A1 |
Provided in the present application are a tricyclic compound, an isomer, pharmaceutically acceptable salt, and pharmaceutical composition thereof and the use thereof, wherein the tricyclic compound has a structure as shown by formula I. ...
|
|
WO/2021/252775A1 |
Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, especially huntingtin protein aggregation, compositions thereof, and methods of their use.
|
|
WO/2021/247717A1 |
The invention relates to solid forms of 2-indolyl imidazo[4,5-D]phenanthroline, methods of their preparation, pharmaceutical compositions thereof and methods of their use.
|
|
WO/2021/244609A1 |
The present invention relates to a compound of formula (I) in which L1, A, X1, X2, X3, R1, R2, R 3, R4, R5, R6, R9, R10, m, and n are as defined in the description, and a stereoisomer, a pharmaceutically acceptable salt, a solvate, or a ...
|
|
WO/2021/239068A1 |
Disclosed herein are heterocyclic compounds that may be used as STING modulators, the process for synthesis and to the use of such compounds in treatment of various diseases including cancers.
|
|
WO/2021/241741A1 |
The present invention provides a photoelectric conversion element having excellent sensitivity, an image sensor, an optical sensor, and a compound. The photoelectric conversion element of the present invention has a conductive film, a ph...
|
|
WO/2021/242581A1 |
This invention provides for compounds of the formula (I): wherein the variables are defined herein, or salt thereof, compositions comprising these compounds, and method for the treatment, control or prevention of a parasitic infestation ...
|
|
WO/2021/240337A1 |
The present invention is directed to novel translational inhibitors that bind covalently with eukaryotic initiation factor 4E (eIF4E) and inhibit or modulate the activity of eIF4E, as well as stereoisomers, tautomers and pharmaceutically...
|
|
WO/2021/237038A1 |
Arylsulfonamides of 4-heteroaryl-piperidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatric disorders such as...
|
|
WO/2021/233800A1 |
The present invention relates to novel ophthalmic devices comprising polymerized compounds comprising a photoactive chromophore, said polymerized compounds, and special monomer compounds being particularly suitable for compositions and o...
|
|
WO/2021/235549A1 |
To provide an exceptional light-emitting material. A compound represented by the general formula is used as a light-emitting material. R is a heteroaryl group bonded with a hydrogen atom, a deuterium atom, an aryl group, or a carbon atom...
|
|
WO/2021/231323A1 |
Described herein are methods of treating cancer in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-
2-yl)-2-methyl-1H-i...
|
|
WO/2021/231653A1 |
Disclosed herein are compounds and combinations of compounds for treating a disease or condition, such as cancer.
|
|
WO/2021/228223A1 |
The present invention relates to a deuterated AKT kinase inhibitor, and in particular to a compound represented by formula I, or pharmaceutically-acceptable salts thereof. The present invention further provides a preparation method, and ...
|
|
WO/2021/231571A1 |
Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.
|
|
WO/2021/228248A1 |
Provided in the present invention is a compound as represented by formula (I) or a tautomer, a stereoisomer, a solvate, a nitrogen oxide, a prodrug, an isotope derivative or a pharmaceutically acceptable salt thereof. The compound exhibi...
|
|
WO/2021/232012A1 |
The inventors had earlier discovered a class of anticancer xanthine-related drugs that restores p53 activity in tumors with mutated p53 and perturbs an S-phase checkpoint. Based upon the properties of this class of p53- pathway restoring...
|
|
WO/2021/227906A1 |
The present invention relates to the technical field of pyridine acetamide derivatives, and specifically relates to a pyridine acetamide derivative serving as a CDK inhibitor, and a preparation method therefor and a use thereof. The pyri...
|
|
WO/2021/231526A1 |
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or dis...
|
|
WO/2021/226262A1 |
The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.
|
|
WO/2021/226206A2 |
Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediat...
|
|
WO/2021/224291A1 |
The present invention relates to tricyclic heterocycles. These heterocyclic compounds are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of...
|
|
WO/2021/224636A1 |
The present invention relates to compounds of formula I shown below: wherein R0, R1, R2, R3 and A are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmace...
|
|
WO/2021/223751A1 |
The present invention belongs to the field of medical technology, and in particular relates to a synthesis method for an anti-tumor compound and an intermediate thereof. The synthesis method of the present invention has enhanced operabil...
|
|
WO/2021/223664A1 |
A method for treating patients with viral infections, particularly coronavirus infections, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of any one of formulas (I)-(VI) or Comp...
|
|
WO/2021/219070A1 |
Bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
|
|
WO/2021/222888A1 |
The disclosure provides a rapidly deployable nanoscale biodegradable system using hydroxypropyl beta cyclodextrin based combination product. Cyclodextrin is an amphiphilic polymer suitable to develop an agnostic barrier blocking pathogen...
|
|
WO/2021/219088A1 |
The present invention relates to a pyrimidine-based tricyclic compound and a use thereof, and specifically, relates to a pyrimidine-based tricyclic compound and a use thereof in preparation of a drug for treating a related disease. Speci...
|
|
WO/2021/221108A1 |
The present invention provides: a photoelectric conversion element having excellent sensitivity; an imaging element, an optical sensor; and a compound. This photoelectric conversion element comprises, in the given order, an electroconduc...
|
|
WO/2021/219071A1 |
Disclosed herein is a process for preparing novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation.
|
|
WO/2021/219578A1 |
The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein X and R3 to R9 are as described herein or pharmaceutically acceptable salts thereof, wherein X and R3 to R9 are as defined herein. Further p...
|
|
WO/2021/220185A1 |
This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to...
|
|
WO/2021/221097A1 |
Provided are: a novel compound, and a pharmaceutically acceptable salt thereof, represented by formula (1), the compound having a histamine H4 receptor-regulating effect and being useful in the treatment and/or prevention of an illness o...
|
|
WO/2021/220170A1 |
The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt form thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmace...
|
|
WO/2021/218829A1 |
The present application provides an organic compound having the structures as shown in formula I-1 and formula I-2, a device using same, and an electronic apparatus, which belong to the technical field of organic materials. The applicati...
|
|
WO/2021/213460A1 |
The present invention belongs to the technical field of medicine, and specifically relates to a tricyclic DNA-PK kinase inhibitor compound represented by general formula (I), a pharmaceutically acceptable salt thereof or an isomer thereo...
|
|
WO/2021/213317A1 |
The present invention relates to a compound represented by general formula (1) and a preparation method therefor, and use of the compound represented by general formula (1) or each isomer, each crystalline form, a pharmaceutically accept...
|
|
WO/2021/213800A1 |
The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I), wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mut...
|
|
WO/2021/210573A1 |
The present invention addresses the problem of providing a novel halogenated biotin-modified dimer to enable imaging diagnosis or treatment. The present invention provides a compound represented by formula (1) or a salt thereof. (In the ...
|
|
WO/2021/211380A1 |
Provided herein is a crystalline form of selpercatinib useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders, and methods of making this cryst...
|
|
WO/2021/211930A1 |
The present invention provides solid forms of compound (1) and compositions thereof which are useful as inhibitors of Plasma Kallikrein (pKal) and which exhibit desirable characteristics for the same.
|
|
WO/2021/208459A1 |
A novel series of micromolecular immune agonists of Toll-like receptor 7, shown as formula I. Also provided is use of the immune agonists for activation and proliferation of immune cells and lymphocytes, and preparation of immunomodulato...
|
|
WO/2021/208918A1 |
Provided are a class of compounds, represented by formula (I"'), as selective EGFR inhibitors, a pharmaceutical composition containing the compounds, useful intermediates for preparing the compounds, and a method for using the compounds ...
|
|
WO/2021/211938A1 |
The present invention provides compounds and compositions thereof which are useful as inhibitors of Plasma Kallikrein (pKal) and which exhibit desirable characteristics for the same.
|
|
WO/2021/207550A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2021/207172A1 |
Bifunctional compounds, which find utility as modulators of Kirsten ras sarcoma protein (KRas or KRAS), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that bin...
|
|
WO/2021/207530A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e g., splicing of a pre-mRNA, as well as methods of use thereof.
|
